Acetylsalicylic acid treatment improves differentiation and immunomodulation of SHED.
Stem cells from exfoliated deciduous teeth (SHED) possess multipotent differentiation and immunomodulatory properties. They have been used for orofacial bone regeneration and autoimmune disease treatment. In this study, we show that acetylsalicylic acid (ASA) treatment is able to significantly improve SHED-mediated osteogenic differentiation and immunomodulation. Mechanistically, ASA treatment upregulates the telomerase reverse transcriptase (TERT)/Wnt/β-catenin cascade, leading to improvement of SHED-mediated bone regeneration, and also upregulates TERT/FASL signaling, leading to improvement of SHED-mediated T-cell apoptosis and ameliorating disease phenotypes in dextran sodium sulfate-induced colitis mice. These data indicate that ASA treatment is a practical approach to improving SHED-based cell therapy.
Department of Pediatric Dentistry, School of Stomatology, China Medical University, Shenyang, China Center for Craniofacial Molecular Biology, Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
Y
Y
Liu
Center for Craniofacial Molecular Biology, Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
C
C
Chen
Center for Craniofacial Molecular Biology, Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
S
S
Liu
Center for Craniofacial Molecular Biology, Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
D
D
Liu
Center for Craniofacial Molecular Biology, Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
X
X
Xu
Department of Pediatric Dentistry, School of Stomatology, China Medical University, Shenyang, China.
X
X
Chen
Center for Craniofacial Molecular Biology, Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA songtaos@usc.edu.
S
S
Shi
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology*; D001861:Bone Regeneration / Q000187:drug effects; D018929:Cell Culture Techniques; D002454:Cell Differentiation / Q000187:drug effects; D064987:Cell- and Tissue-Based Therapy; D002648:Child; D003092:Colitis / Q000628:therapy; D004305:Dose-Response Relationship, Drug; D053222:Fas Ligand Protein / Q000187:drug effects; D006801:Humans; D006882:Hydroxyapatites / Q000737:chemistry; D056747:Immunomodulation / Q000187:drug effects; D059630:Mesenchymal Stem Cells / Q000187:drug effects*; D051379:Mice; D008810:Mice, Inbred C57BL; D008815:Mice, Inbred Strains; D008819:Mice, Nude; D039902:Multipotent Stem Cells / Q000187:drug effects; D010012:Osteogenesis / Q000187:drug effects; D013601:T-Lymphocytes / Q000187:drug effects; D019098:Telomerase / Q000187:drug effects; D054457:Tissue Scaffolds / Q000737:chemistry; D014094:Tooth, Deciduous / Q000166:cytology*; D060449:Wnt Signaling Pathway / Q000187:drug effects
D053222:Fas Ligand Protein; D006882:Hydroxyapatites; C074950:hydroxyapatite-beta tricalcium phosphate; D019098:Telomerase; D001241:Aspirin
Fas ligand; Wnt pathway; cell therapy; deciduous teeth; mesenchymal stem cells; telomerase